AbCellera Biologics Stock Jumps 15% to New 52-Week High on Hot Flash Drug Momentum and Price Target Hike

AbCellera Biologics' stock surged after positive Phase 2 trial results for its menopause drug, ABCL635. The company's market value increased significantly, driven by investor enthusiasm and analyst upgrades.




